1. Home
  2. OTLY vs RLMD Comparison

OTLY vs RLMD Comparison

Compare OTLY & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

HOLD

Current Price

$11.89

Market Cap

454.4M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

461.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLY
RLMD
Founded
1994
2004
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.4M
461.9M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
OTLY
RLMD
Price
$11.89
$3.86
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
★ $14.50
$12.40
AVG Volume (30 Days)
43.2K
★ 1.2M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 45.28
EPS
★ N/A
N/A
Revenue
N/A
★ $13,070.00
Revenue This Year
$7.91
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$8.01
$1.80
52 Week High
$17.18
$8.00

Technical Indicators

Market Signals
Indicator
OTLY
RLMD
Relative Strength Index (RSI) 34.14 34.70
Support Level $10.01 $3.34
Resistance Level $12.53 $4.51
Average True Range (ATR) 0.49 0.23
MACD -0.15 -0.02
Stochastic Oscillator 2.30 21.21

Price Performance

Historical Comparison
OTLY
RLMD

About OTLY Oatly Group AB

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: